Organization
Cancer Research Institute, Seoul National University College of Medicine, Seoul National University
2 abstracts
Abstract
A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial.Org: Yonsei University College of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Gangnam Severance Hospital, Seoul St. Mary's Hospital,
Abstract
Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study.Org: Memorial Sloan Kettering Cancer Center, University of Vermont Cancer Center, Université Libre de Bruxelles (ULB), Institut Jules Bordet, Université Libre de Bruxelles, Medical Oncology Department,